The Shift to Outpatient Large-Joint Replacement Surgeries
The Shift to Outpatient Large-Joint Replacement Surgeries Less invasive techniques, better pain management, pressure to minimize costs, and changing reimbursement rules are leading to interesting...
Navigating the Rough Seas of Copay Accumulator Programs. Impacts, Trends and Mitigation Strategies for Pharma
This live session took place on February 7th, 2019 During 2018, PBMs began ramping up efforts to address drug spending through Copay Accumulator programs, which prevent manufacturer copay assistance...
Global Market Access: Key Events in 2018
Global Market Access: Key Events in 2018 The global market access landscape for pharmaceuticals continued its evolution in 2018 as countries across the globe sought to balance the need for expanding...
Immune Checkpoint Inhibitor Trial Landscape – Over 70 Key Trials on the Horizon
Immune checkpoint inhibitors continue to revolutionize the current clinical oncology landscape. DRG experts used Oncology Clinical Trial Monitor data to provide an overview of the late-phase immune...
Machine Learning: The Next Frontier in Pharma Intelligence
Practical guide to help pharma execs determine when and how to use machine learning to drive business decisions.
Antibody-drug Conjugates: Takeaways and Best Practices for Strategy Planning
Antibody-drug conjugates have delivered meaningful improvements in outcomes for select patients over recent years, providing cancer patients with fewer and less severe side effects than traditional...
Hormonal Agents in Prostate and Breast Cancer: Takeaways and Best Practices for Strategy Planning
Hormonal therapy is a cornerstone of drug treatment for prostate cancer across all drug-treated populations (hormone-sensitive and castrate resistant settings) and is also widely used as a treatment...
Top 8 drug pricing disruptors going into 2019
Pitfalls and opportunities in the commercial healthcare market. As the managed care market pursues vertical integration and diversification, DRG sees disruptive change ahead for the U.S. healthcare...
PARP Inhibitors: Takeaways and Best Practices for Strategy Planning
The inhibition of PARP has emerged as a therapeutic approach in tumors that are intrinsically deficient in DNA repair, such as_BRCA1/2-mutation-positive breast or ovarian cancers. Particularly in...
ON THE ROAD TO MACRA: The Transition is Over, MACRA is Here to Stay
After several years of transition, the Medicare Access and CHIP Reauthorization Act of 2015 begins full implementation in 2019. Overall, the first round of the Merit-based Incentive Payment System...
A global consultancy and training agency providing market leading product & portfolio strategy, health economic outcomes research & evidence generation, value communication and training services across the life science industry.
We partner with both the biopharmaceutical and medical technology industry to support commercialization & patient access across a variety of functions including: R&D, commercial strategy, HEOR, market access, new product planning, marketing, data insights & analytics, business development and channel & segment customer engagement.
